黄芪甲苷对BALB/C小鼠肝癌H22腹水瘤抑制作用及机制  

Inhibition and Mechanism of Astragaloside Ⅳ on H22 Ascites in BALB/C Mice

作　　者：武建毅[1] 沈清[1] 金赟洁[1] 姚晓祥[1] 朱纪[1] 华朱 麟玉 黄晓东[1] 

机构地区：[1]上海市普陀区人民医院,上海200060

出　　处：《中国药物警戒》2016年第3期138-142,145,共6页Chinese Journal of Pharmacovigilance

基　　金：江苏大学医学临床科技发展基金(JLY20140100)

摘　　要：目的探讨黄芪甲苷对BALB/C小鼠肝癌H22腹水瘤的抑制作用及机制。方法 BALB/C小鼠100只,腹腔注射H22细胞建立小鼠肝癌H22腹水瘤模型后,随机分为阴性对照组(0.9%NS)、阳性对照组(0.5 mg·kg-1顺铂)、黄芪甲苷低(0.3 mg·kg-1)、中(1.0 mg·kg-1)、高(3.0 mg·kg-1)剂量组,每组20只,每日1次,连续给药14 d,末次给药24 h后处死小鼠,计算腹水量、瘤细胞抑制率及腹膜瘤最大结节直径,ELISA检测VEGF的含量,免疫组化检测VEGF、MMP-2、MMP-9、AQP-1和CD31蛋白的表达。结果黄芪甲苷组腹水量、瘤细胞存活率以及最大结节直径均降低(P<0.05);VEGF含量明显减少,与阴性对照组比较有显著差异(P<0.001),VEGF、MMP-2、MMP-9、AQP-1和CD31蛋白的表达降低。结论黄芪甲苷通过影响血管生成、抑制转移相关基因和水通道蛋白的表达抑制H22腹水瘤肝癌。Objective To investigate the inhibition of astragaloside IV （As IV） on H22 ascites in BALB/C mice and its mechanism. Methods H22 ascites mouse model was established by i.p. injecting 100 BALB/C mice with H22 cells. Mice were then divided randomly into 5 groups： negative control （0.9 % normal saline）, positive control （DDP 0.5 mg·kg-1）, low As IV dose （0.3 mg·kg-1）, intermediate As IV dose （1.0 mg-kg1） and high As IV dose （3.0 mg·kg-1）, 20 of each group, once a day for 14 days. 24 hours after the end of the treatment, mice of each group were executed, calculated the volume of ascites, cell-inhibition rate and the diameter of largest nodule. The content of VEGF in ascites was detected by ELISA, the protein expression was made by immunohistochemical detection of VEGF, MMP-2, MMP-9, AQP-1 and CD31. Results The volume of ascites, largest nodule diameter, tumor cell viability and the content of VEGF were decreased, compared with negative group, the difference was statistically significant （P〈0.05）. Also the protein expression of VEGF, MMP-2, MMP-9, AQP-1 and CD31 were decreased, compared with negative group. Conclusion H22 ascites in BALB/C mice were inhibited by astragaloside IV （As IV ） through the angiogenesis, inhibiting metastasis associated genes and the expression of aquaporin（AQPs）.

关 键 词：黄芪甲苷 H22腹水瘤 BALB/C小鼠 抑制作用 机制 

分 类 号：R965[医药卫生—药理学]